前列腺体积≥80 cm³男性的水蒸气热疗:系统综述与Meta分析
该系统综述与Meta分析纳入15项研究(其中11项为回顾性研究)、共471例前列腺体积≥80 cm³且接受Rezum治疗的男性,随访中位6个月(范围3-17个月)。结果显示IPSS、IPSS-QOL、Qmax及排尿后残余尿量均获统计学显著改善,IIEF-EF无变化,严重并发症发生率<0.1%,手术再治疗率1.2%。
要点
- 前列腺体积≥80 cm³男性接受Rezum治疗后IPSS平均下降11.0分(95%CI -12.2至-9.7,P<.001)。
- Qmax平均增加6.5 mL/s(95%CI 4.8至8.2,P<.001),排尿后残余尿量平均减少101 mL(95%CI -145至-57,P<.001)。
- 严重并发症(Clavien-Dindo III-V级)发生率<0.1%(95%CI 0.0%至0.4%),手术再治疗率1.2%(95%CI 0.0%至3.5%)。
核心结论
- Rezum治疗对前列腺体积≥80 cm³男性的下尿路症状提供统计学显著且临床重要的短期改善,且并发症发生率低。
- Rezum治疗大前列腺体积的长期结局仍不明确。
研究设计与样本
- 系统综述与随机效应模型Meta分析,纳入15项研究(其中11项为回顾性研究),共471例前列腺体积≥80 cm³并接受Rezum治疗的男性,随访中位6个月(范围3-17个月)。
主要发现
- IPSS平均变化-11.0(95%CI -12.2至-9.7,P<.001)。
- IPSS-QOL平均变化-2.9(95%CI -3.5至-2.4,P<.001)。
- Qmax平均变化6.5 mL/s(95%CI 4.8至8.2 mL/s,P<.001)。
- 排尿后残余尿量平均变化-101 mL(95%CI -145至-57,P<.001)。
- IIEF-EF无变化(平均变化0.3;95%CI -1.1至1.6;P=.71);严重并发症发生率<0.1%(95%CI 0.0%至0.4%),手术再治疗率1.2%(95%CI 0.0%至3.5%)。
关键数值与推荐
- 前列腺体积≥80 cm³男性接受Rezum治疗后IPSS平均下降11.0分(95%CI -12.2至-9.7,P<.001)。
- IPSS-QOL平均下降2.9分(95%CI -3.5至-2.4,P<.001)。
- Qmax平均增加6.5 mL/s(95%CI 4.8至8.2 mL/s,P<.001)。
- 排尿后残余尿量平均减少101 mL(95%CI -145至-57,P<.001)。
- IIEF-EF平均变化0.3(95%CI -1.1至1.6,P=.71)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 15项研究中11项为回顾性研究。
- 随访中位时间仅6个月(范围3-17个月)。
- Rezum治疗大前列腺体积的长期结局仍不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine the safety and effectiveness of water vapor thermal therapy (Rezum) in men with large prostate volumes of at least 80cm3. METHODS: We performed systematic searches for studies of Rezum therapy in men with prostate volume of at least 80 cm3. Meta-analysis outcomes included the International Prostate Symptom Score (IPSS), IPSS Quality of Life (IPSS-QOL), Qmax, postvoid residual, International Index of Erectile Function-Erectile Function (IIEF-EF), and serious (Clavien-Dindo grade III-V) complications, surgical retreatments. Outcomes were analyzed using a random effects meta-analysis model. RESULTS: The review included 15 studies (11 retrospective) of 471 men with prostate volume at least 80 cm3 treated with Rezum therapy and followed for a median of 6months (range: 3-17months). Rezum therapy resulted in statistically significant improvements in IPSS (mean change: -11.0; 95% CI: -12.2, -9.7; P < .001), IPSS-QOL (mean change: -2.9; 95% CI: -3.5, -2.4; P < .001), Qmax (mean change: 6.5 mL/s; 95% CI: 4.8, 8.2 mL/s; P < .001), and postvoid residual (mean change: -101 mL; 95% CI: -145, -57; P < .001). No change in IIEF-EF was observed (mean change: 0.3; 95% CI: -1.1, 1.6; P = .71). Serious complications occurred in <0.1% (95% CI: 0.0%, 0.4%) and surgical retreatment in 1.2% (95% CI: 0.0%, 3.5%) of patients. CONCLUSION: Rezum therapy provides a statistically significant and clinically important short-term improvement in lower urinary tract symptoms with low complication rates in men with prostate volume of at least 80 cm3. Long-term outcomes with Rezum therapy in large prostates remain unclear.
引用
- McVary KT, Miller LE, Bhattacharyya S, et al. Water Vapor Thermal Therapy in Men With Prostate Volume ≥80 cm3: A Systematic Review and Meta-Analysis. Urology. 2023. PMID: 38006957. doi:10.1016/j.urology.2023.10.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。